When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
The most important facts at a glance
Malignant Fibrous Histiocytoma (MFH) is an aggressive soft tissue tumor in dogs that arises from mesenchymal precursor cells. The exact causes are unclear, but genetic factors, environmental influences, and chronic inflammatory conditions could play a role. Older dogs are more frequently affected. Symptoms include swelling, pain, and loss of appetite. Diagnosis is made through clinical examination, biopsy, and imaging procedures such as X-ray or MRI to assess the extent and possible metastases.
Treatment often requires surgical removal of the tumor, supplemented by radiation therapy or chemotherapy in metastatic cases. The prognosis ranges from guarded to poor, especially for metastatic tumors. Regular follow-up examinations are important to detect recurrence early. Since the exact causes are not fully understood, there are no specific prevention measures. Nevertheless, regular veterinary examinations and avoidance of carcinogens can reduce the overall cancer risk.
Research focuses on the genetic basis of MFH to develop more targeted treatments. New diagnostic methods and treatment forms such as immunotherapy are being investigated. A healthy lifestyle could be supportive, and studies on the role of nutrition could offer new therapeutic approaches.
Causes
Malignant fibrous histiocytomas belong to the sarcomas, a group of tumors originating from mesenchymal cells. These cells are the precursors of connective tissue, muscle, fat tissue, and other soft tissues. MFH is characterized by a mixture of fiber-forming and histiocytic (macrophage-like) cells. The exact cell line from which MFH originates is not fully understood, but it is assumed that the tumor cells derive from undifferentiated mesenchymal precursor cells.
The causes for the development of a malignant fibrous histiocytoma are not fully understood. Genetic factors, environmental influences, as well as chronic inflammatory conditions or traumas could play a role in tumor development. There are no specific breed predispositions, but older dogs are more frequently affected.
Genetic mutations that lead to uncontrolled cell division are often the driving force behind tumor development. These mutations can occur spontaneously or be induced by external influences such as environmental toxins or radiation. However, the exact genetic signature of MFH in dogs is still a subject of research.
Symptoms
Symptoms of a malignant fibrous histiocytoma can vary depending on the location and size of the tumor. The tumor often appears as a fast-growing, painless lump in the subcutaneous tissue. However, it can also occur in deeper soft tissues and exert pressure on surrounding structures there.
In advanced stages, symptoms such as lameness, swelling, weight loss, and general weakness may occur. Metastases, especially to the lungs, can lead to respiratory distress. In some dogs, systemic symptoms such as fever or anemia may also be observed, indicating a malignant disease.
Since the symptoms are nonspecific, it is important to consult a veterinarian for any newly appearing or unusually fast-growing lump to obtain an accurate diagnosis.
Therapy
The treatment of malignant fibrous histiocytoma requires a multimodal approach. Surgical removal of the tumor is the primary treatment option. It is advisable to completely remove the tumor with sufficient safety margins to minimize the likelihood of recurrence.
In cases where complete surgical resection is not possible, radiation therapy can be used to destroy the remaining tumor cells. Chemotherapy may be considered, especially for metastatic tumors or if surgical removal was not complete. However, the effectiveness of chemotherapy for MFH is limited and depends on the individual tumor biology.
Treatment is often palliative, especially for metastatic or inoperable tumors, and aims to improve the animal’s quality of life and relieve symptoms.
Prognosis and follow-up care
The prognosis for dogs with malignant fibrous histiocytoma is generally guarded to poor, especially if the tumor has metastasized or cannot be completely surgically removed. Survival time depends on various factors, including tumor size, location, metastasis, and the dog’s overall health status.
Dogs in which the tumor could be completely removed and showed no signs of metastasis have a better prognosis. Nevertheless, the recurrence rate is high, and regular follow-up examinations are required to detect recurrence early.
The dog’s quality of life is paramount in treatment, and decisions should be made in the best interest of the animal, weighing the burden of treatments against their impact on quality of life.
Prevention
Since the exact causes for the development of malignant fibrous histiocytoma are not fully understood, there are no specific preventive measures to prevent the occurrence of these tumors.
However, regular veterinary examinations and early detection of tumors can help improve the prognosis. Monitoring older dogs for unusual swelling or lumps and prompt evaluation by a veterinarian are important for detecting malignant tumors early.
Avoiding known carcinogens and maintaining a healthy lifestyle, including a balanced diet and regular exercise, can reduce the overall cancer risk in dogs, even though they do not represent specific prevention against MFH.
Outlook on current research
Research on malignant fibrous histiocytoma (MFH) in dogs is steadily advancing, as it is an aggressive form of soft tissue sarcoma that occurs in both humans and animals. Currently, many studies focus on better understanding the genetic and molecular basis of these tumors. Researchers are investigating specific mutations and genetic markers that could contribute to the development of MFH in order to develop more targeted and effective treatment strategies. The identification of such genetic anomalies could enable the development of personalized therapies that are better tailored to the individual needs of each dog.
Another research focus is the improvement of diagnostic procedures. Currently, MFH is often diagnosed through a combination of imaging and biopsy, but efforts are underway to develop less invasive methods. Advances in imaging technology, such as the use of high-resolution MRIs and CT scans, could significantly improve diagnostic accuracy and help detect tumors at an earlier stage. Additionally, work is being done on biomarkers that can be detected in the blood to facilitate monitoring and management of the disease.
Therapeutic approaches are also an important area of research. Traditionally, MFH tumors are treated by surgical removal, often in combination with radiation therapy and chemotherapy. However, current studies are investigating the potential of newer treatment forms such as immunotherapy and targeted therapy. Immunotherapies use the body’s own immune system to attack cancer cells, while targeted therapies attack specific anomalies in cancer cells. By combining these methods with traditional treatment forms, researchers hope for improved outcomes in affected dogs.
In veterinary medicine, the role of nutrition and overall health in the treatment of MFH is also being investigated. A healthy lifestyle could play a supportive role in the treatment and possibly also in the prevention of tumors. Studies investigating the influence of diet and nutritional supplements on tumor growth in dogs could provide valuable insights and lead to new supportive therapeutic approaches.
Frequently Asked Questions (FAQs)
1. What is a malignant fibrous histiocytoma?
2. What symptoms does a dog with MFH show?
3. How is MFH diagnosed in dogs?
4. What treatment options are available for dogs with MFH?
5. What is the prognosis for dogs with MFH?
6. Can MFH tumors be prevented in dogs?
7. Are there breeds that are more susceptible to MFH?
8. Is MFH painful in dogs?
9. What role does nutrition play in the treatment of MFH?
10. How can I help my dog with MFH?
Literature
- Gleiser, C. A., Raulston, G. L., Jardine, J. H., & Gray, K. N. (1979). Malignant fibrous histiocytoma in dogs and cats. Veterinary Pathology, 16(2), 199–208. https://doi.org/10.1177/030098587901600205
- Thoolen, R. J. M. M., Vos, J. H., Van der Linde-Sipman, J. S., De Weger, R. A., Van Unnik, J. A. M., Misdorp, W., & Van Dijk, J. E. (1992). Malignant fibrous histiocytomas in dogs and cats: An immunohistochemical study. Research in Veterinary Science, 53(2), 198–204. https://doi.org/10.1016/0034-5288(92)90110-n
- Do, S. H., Hong, I. H., Park, J. K., Ji, A. R., Kim, T. H., Kwak, D. M., & Jeong, K. S. (2009). Two different types of malignant fibrous histiocytomas from pet dogs. Journal of Veterinary Science, 10(2), 169–171. https://doi.org/10.4142/jvs.2009.10.2.169
- Choi, H., Kwon, Y., Chang, J., Jeong, S., Lee, H., Kim, J., Jung, J., & Lee, Y. (2011). Undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) of the head in a dog. Journal of Veterinary Medical Science, 73(2), 235–239. https://doi.org/10.1292/jvms.10-0183
- Kim, K., Shin, J., Kim, H., Kim, H., Kim, J., Do, S., & Kim, H. (2022). Multiple undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) with extradural involvement in a 7-year-old Labrador Retriever. Veterinary Sciences, 9(1), Article 3. https://doi.org/10.3390/vetsci9010003
- Bray, J. P. (2016). Soft tissue sarcoma in the dog—Part 1: A current review. Journal of Small Animal Practice, 57(10), 510–519. https://doi.org/10.1111/jsap.12556
- Bray, J. P. (2017). Soft tissue sarcoma in the dog—Part 2: Surgical margins, controversies and a comparative review. Journal of Small Animal Practice, 58(2), 63–72. https://doi.org/10.1111/jsap.12629
- Das, S., Idate, R., Lana, S. E., Regan, D. P., & Duval, D. L. (2023). Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions. Scientific Reports, 13, Article 10422. https://doi.org/10.1038/s41598-023-37266-y
- Dell’Anno, F., Giugliano, R., Listorti, V., & Razzuoli, E. (2024). A review on canine and human soft tissue sarcomas: New insights on prognosis factors and treatment measures. Veterinary Sciences, 11(8), Article 362. https://doi.org/10.3390/vetsci11080362